Navigation Links
Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa

An expanded clinical trial conducted by Optobionics Corporation involving the implantation of a retina mircrochip has allowed Emory Eye Center and the Atlanta Veterans Affairs Rehabilitation Research & Development Center to implant the device in several patients. The patients all have retinitis pigmentosa with moderate-to-severe vision loss. Three centers in the United States have been chosen to conduct the expanded trial. Other than Emory and the VA Rehabilitation R&D Center they include Rush University Medical Center's Department of Ophthalmology and the Wilmer Eye Institute at Johns Hopkins Medical Center.

Retinitis pigmentosa is a pathologic condition that is hereditary and causes progressive retinal degeneration in both eyes. It is a general term for a number of diseases that predominantly affect the photoreceptor layer or "light sensing" cells of the retina. Night blindness develops, usually in childhood, followed by loss of peripheral visual field, progressing over many years to tunnel vision and finally blindness.

At Emory Eye Center retina specialists Thomas M. Aaberg, Sr. and Jiong Yan performed the surgery recently on five patients. Another two patients are planned for mid-February.

"This experimental device may make it possible for those with retinitis pigmentosa to have a much better quality of life," says Dr. Aaberg. "We are excited to be able to participate in this clinical trial as part of Emory Eye Center's ongoing research and surgical procedures to fight blinding eye disease. Because Emory and the Atlanta VA Rehabilitation R&D Center met the FDA and Optobionics criteria that included surgical expertise, a strong research component and an established patient base of degenerative retinal diseases, we were able to be a part of this important study."

Pre- and post-surgery patients are evaluated by a team of researchers working at the Eye Center and the VA Rehabilitation R&D Center including Ronald A. Schu
'"/>

Source:Emory University Health Sciences Center


Page: 1 2

Related biology news :

1. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
2. Fox Chase Cancer Center scientists identify immune-system mutation
3. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
4. $6.5 Million Grant for Microarray Center at Yale School of Medicine
5. Woods Hole Research Center plans controlled burn in Amazon rainforest
6. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
7. Center releases new public survey on stem cells
8. World Trade Center identifications pushed forensic DNA technology
9. VCU Massey Cancer Center researchers identify a new class of anti-cancer drugs based on platinum
10. Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer
11. Timing is everything: First step in protein building revealed

Post Your Comments:
(Date:11/4/2009)..., PORTOLA VALLEY, Calif., Oct. 19 ...olecular sensing and imaging devices which shed li...that it has signed exclusive distribution deals fo...nsors. The markets covered include Australia, New...enelux), Suriname, Italy, France, Spain, Portugal,...
(Date:11/4/2009)..., CARLSBAD, Calif., Oct. 23 GenVau...biosample management for genomic discovery, medici...Wellis, Ph.D., GenVault,s President and CEO, will ...king place on October 26th and 27th in La Jolla, C...provide an overview of the company together with r...
(Date:11/4/2009)..., SEATTLE, Nov. 4 Glencoe Software...Environment (OME) Consortium ( http://openmicrosc... with the American Society of Cell Biology,s excit...." The ASCB has been awarded a $2.5M stimulus gran...) Grand Opportunities program, as part of the Amer...
Breaking Biology News(10 mins):Spectros Signs New International Distribution Deals 2GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2Grupo Casa Saba Announces Quarterly Earnings Report 2Q09 52853 1Grupo Casa Saba Announces Quarterly Earnings Report 2Q09 52853 2Grupo Casa Saba Announces Quarterly Earnings Report 2Q09 52853 3Grupo Casa Saba Announces Quarterly Earnings Report 2Q09 52853 4Grupo Casa Saba Announces Quarterly Earnings Report 2Q09 52853 5Image Sensors 2009 Announces Final Program and New Interactive Brochure 52852 1Image Sensors 2009 Announces Final Program and New Interactive Brochure 52852 2Mayo Researchers Find Anesthesia Not Harmful for Babies During Birth Process 52850 1Mayo Researchers Find Anesthesia Not Harmful for Babies During Birth Process 52850 2Mayo Researchers Find Anesthesia Not Harmful for Babies During Birth Process 52850 3Mayo Researchers Find Anesthesia Not Harmful for Babies During Birth Process 52850 4Mayo Researchers Find Anesthesia Not Harmful for Babies During Birth Process 52850 5Mayo Researchers Find Anesthesia Not Harmful for Babies During Birth Process 52850 6
...tive to Irradiation , Researchers led by Dr. Bat...rradiation damages fat tissue. They report their f... Journal of Pathology . , Radiation therapy dir...sues. Autologous transplant of tissues such as fat...s, organ dysfunction, and necrosis that result fro...
...-term gene therapy resulted in improved cardiac fu...rats with heart failure, according to a recent stu...iversity,s Center for Translational Medicine. The ...e rats were treated with a gene that generates a p...d to hearts in combination with recombinant-adeno-...
...RK (DECEMBER 26, 2008) A team of scientists from ...WCS) has reported a rapid recovery of coral reefs ...devastated coastal regions throughout the Indian O...team, working in conjunction with the Australian R...f Studies (ARCCoERS) along with government, commun...
Other Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5Gene therapy reversed heart damage in heart failure 24 years after tsunami: Corals stage comeback 24 years after tsunami: Corals stage comeback 3
(Date:11/5/2009)...eb., Nov. 5 Transgenomic...financial results for the quarter ended September ...ented in the tables that follow. ,, Third Quar... $366,000 or $0.01 per share for the third quarter...$0.01 per share for the third quarter of 2008. ,...
(Date:11/5/2009)... Calif., Nov. 5 WaferGen...ading developer of state-of-the-art genetic analys..., Ph.D. has joined the company,s Scientific Adviso...g and commercializing novel molecular diagnostics ...n the development of computational biology systems...
(Date:11/5/2009)... Brooke Sanders brings a new look to Pr...EB) November 5, 2009 -- Professional Reprographics...ics company is pleased to present Brooke Sanders t...raphics/PR specialist. The addition of Brooke to t...wth within Professional Reprographics., , ,Brooke ...
(Date:11/4/2009)..., ROCKVILLE, Md., Nov. 4 Zyngenia,...cused on next-generation antibody drug development...in Series A funding from New Enterprise Associates... firms. The capital will be used to create novel, ...s two or more biological targets with a single age...
Breaking Biology Technology:Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4
... Increased Bioavailability, MOUNTAIN VIEW, Calif....e either incurable or difficult to treat allures c...ghly prized, due to their,therapeutic potential, s...riety of diseases. Stem cell research progresses a...em cells have their own unique challenges that,mus...
...LGARY, Oct. 21 /PRNewswire-FirstCall/ - Resverlogi...that the ongoing double blind,placebo controlled P...DL is,progressing as planned. The subjects in the ...afety and tolerability. Thus the safety committee ...t in which 24 subjects will,receive treatment dose...
...rumo Heart, Inc. announced,today that five patient...,Assist System (LVAS), marking an important early ... Dr. Francis Pagani performed the five implants,at...in Ann Arbor with three,of the surgeries performed...ting the first off-pump implants,of DuraHeart in t...
Other Biology Technology:Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 2Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 3Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial 2Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial 2
...the submicron range are part of your production or...rol of particle size is important to you. You need...t populations in your sample every time. The N5 Su...tion Spectroscopy (PCS) , which determines particl...
...ndria Derived Activator of Caspase/DIABLO Liquid...THAW CYCLES. Amino acid residues 56 - 239 of human...® sequence was expressed in and purified from...ochrome c during apoptosis and promotes caspase ...
...as originally formulated to support the growth of ...,Antherea eucalypti. The medium is a modification ...hemolymph. The cell lines established by Grace usi...eloped. The basal medium, when properly supplement...
Vsp I from Promega
Biology Products: